Gilead Sciences, Inc. (NASDAQ:GILD) Holdings Lowered by Clifford Swan Investment Counsel LLC

Clifford Swan Investment Counsel LLC trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 71,042 shares of the biopharmaceutical company’s stock after selling 3,598 shares during the quarter. Clifford Swan Investment Counsel LLC’s holdings in Gilead Sciences were worth $5,755,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. OFI Invest Asset Management bought a new stake in shares of Gilead Sciences during the 3rd quarter worth $26,000. Tompkins Financial Corp raised its stake in Gilead Sciences by 223.1% during the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 241 shares during the last quarter. Fortitude Family Office LLC bought a new stake in Gilead Sciences in the 4th quarter valued at $29,000. Rakuten Securities Inc. bought a new position in shares of Gilead Sciences during the 4th quarter worth about $33,000. Finally, Financial Connections Group Inc. acquired a new position in shares of Gilead Sciences during the fourth quarter valued at about $40,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the transaction, the insider now directly owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.29% of the company’s stock.

Gilead Sciences Trading Up 1.2 %

Shares of GILD stock traded up $0.76 during mid-day trading on Monday, hitting $65.54. The company’s stock had a trading volume of 7,071,165 shares, compared to its average volume of 7,455,339. The company has a debt-to-equity ratio of 1.08, a quick ratio of 0.72 and a current ratio of 0.98. Gilead Sciences, Inc. has a 52 week low of $64.33 and a 52 week high of $87.86. The company’s fifty day simple moving average is $70.55 and its 200-day simple moving average is $75.78. The company has a market cap of $81.60 billion, a PE ratio of 179.94, a P/E/G ratio of 1.31 and a beta of 0.22.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The business had revenue of $6.69 billion during the quarter, compared to the consensus estimate of $6.36 billion. During the same quarter last year, the firm posted $1.37 EPS. Gilead Sciences’s revenue was up 5.3% compared to the same quarter last year. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 3.74 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be paid a dividend of $0.77 per share. The ex-dividend date is Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a yield of 4.70%. Gilead Sciences’s dividend payout ratio (DPR) is currently 855.56%.

Wall Street Analysts Forecast Growth

GILD has been the subject of a number of analyst reports. TD Cowen reduced their price objective on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a report on Friday, April 26th. Truist Financial downgraded Gilead Sciences from a “buy” rating to a “hold” rating and dropped their target price for the stock from $91.00 to $82.00 in a research report on Thursday, February 22nd. Wells Fargo & Company dropped their price objective on Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a report on Monday, March 4th. Cantor Fitzgerald lowered their price target on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a research report on Wednesday, February 7th. Finally, Royal Bank of Canada reduced their price objective on shares of Gilead Sciences from $76.00 to $74.00 and set a “sector perform” rating on the stock in a research note on Friday, April 26th. Eleven analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $83.69.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.